NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01500993,Capecitabine in the Perioperative Treatment of Rectal Cancer,https://clinicaltrials.gov/study/NCT01500993,Rektum-III,COMPLETED,This study compares capecitabine with standard 5-FU in the perioperative treatment of locally advanced rectal cancer.,NO,Rectal Cancer,DRUG: Capecitabine|DRUG: 5-FU,"Overall survival, 5-year","disease-free survival (DFS), 3-year DFS|Local recurrence rate, Percentage of patient with local recurrence, 5 years",,Universit채tsmedizin Mannheim,,ALL,"ADULT, OLDER_ADULT",PHASE3,401,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,Rektum III,2002-03,2011-03,2011-03,2011-12-29,,2020-11-27,"Dr Martina Grunewald, Aschersleben, Germany|Dr Hans Walter Lindemann, Hagen, Germany|Prof Hartmut Link, Kaiserslautern, Germany|Dr Elisabeth Fritz, Koblenz, Germany|Dr Stephan Kremers, Lebach, Germany|Dr Lothar M체ller, Leer, Germany|Dr Christain Constantin, Lemgo, Germany|Dr Erika Kettner, Magdeburg, Germany|Dr Markus Moehler, Mainz, Germany|Dr Udo Hieber, Mannheim, Germany|Prof Ralf Hofheinz, Mannheim, Germany|Dr Matthias Hipp, Regensburg, Germany|Prof Axel Matzdorff, Saarbr체cken, Germany|Dr Stephan Laechelt, T체bingen, Germany",
